Results 21 to 30 of about 25,087 (209)
Cell Death and Disease, 2022 Venetoclax plus cytarabine therapy is approved for elderly acute myeloid leukemia (AML) patients and needs further improvement. We studied the mechanisms of venetoclax plus cytarabine treatment and searched for a third agent to enhance their effects ...
Jingyi Zhang +7 more
doaj +1 more source
Cancer Cell International, 2020 Venetoclax has been approved by the United States Food and Drug Administration since 2016 as a monotherapy for treating patients with relapsed/refractory chronic lymphocytic leukemia having 17p deletion.
XiaoYan Yue, Qingxiao Chen, JingSong He
doaj +1 more source
Pathology and Oncology Research, 2023 Introduction: The selective Bcl-2 inhibitor venetoclax has shown promising therapeutic potential in multiple myeloma, particularly in cases associated with t(11;14) IGH::CCND1 translocation.
Andrea Ceglédi +6 more
doaj +1 more source
Repurposing tofacitinib as an anti-myeloma therapeutic to reverse growth-promoting effects of the bone marrow microenvironment. [PDF]
, 2018 The myeloma bone marrow microenvironment promotes proliferation of malignant plasma cells and resistance to therapy. Activation of JAK/STAT signaling is thought to be a central component of these microenvironment-induced phenotypes.
Aftab, Blake T +13 more
core +2 more sources
Haematologica, 2022 BCL-2 family proteins are frequently aberrantly expressed in mantle cell lymphoma (MCL). Recently, the BCL-2-specific inhibitor venetoclax has been approved by the US Food and Drug Administration for chronic lymphocytic leukemia (CLL) and acute myeloid ...
Yvonne J. Thus +9 more
doaj +1 more source
Combined Treatment with MEK and mTOR Inhibitors is Effective in In Vitro and In Vivo Models of Hepatocellular Carcinoma. [PDF]
, 2019 Background: Hepatocellular carcinoma (HCC) is the most common primary liver cancer histotype, characterized by high biological aggressiveness and scarce treatment options.
Calvisi, Diego F +14 more
core +1 more source
Venetoclax-containing regimens in acute myeloid leukemia
Therapeutic Advances in Hematology, 2021 Venetoclax in combination with hypomethylating agents (HMAs) or low-dose cytarabine (LDAC) has demonstrated exceptional activity in elderly and unfit patients with newly diagnosed acute myeloid leukemia (AML).
Ibrahim Aldoss +2 more
doaj +1 more source
HOX gene expression predicts response to BCL-2 inhibition in acute myeloid leukemia [PDF]
, 2016 Peer ...
Eldfors, Samuli +16 more
core +1 more source
Bone marrow senescence and the microenvironment of hematological malignancies [PDF]
, 2020 Senescence is the irreversible arrest of cell proliferation that has now been shown to play an important role in both health and disease. With increasing age senescent cells accumulate throughout the body, including the bone marrow and this has been ...
Bowles, Kristian M. +3 more
core +1 more source
Hematology, Transfusion and Cell Therapy, 2023 Objectives: Venetoclax-based therapy is a standard option for pts with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) previously treated with a covalent BTK inhibitor (cBTKi).
O Al-Sawaf +7 more
doaj +1 more source